about the author

ENDPOINTS

editor@endpointsnews.com

author articles

IDO-de­rived can­cer vac­cine scores in com­bo tri­al with Keytru­da; Vir teams up with WuXi on coro­n­avirus an­ti­bod­ies

6 years ago
News Briefing

Gen­fit de­lays high-stakes PhI­II NASH read­out; Bris­tol-My­ers grabs first Op­di­vo OK in esophageal can­cer

6 years ago
News Briefing

Heron's Ground­hog Day; Vi­for forms JV with Fre­se­nius Kabi in Chi­na

6 years ago
News Briefing

In­cyte's top­i­cal Jakafi scores again in eczema Phase III; Pri­or­i­ty re­view lines Roche's Tecen­triq up for new lung ...

6 years ago
News Briefing

Two fast track des­ig­na­tions for Corey Good­man's new start­up; Vi­for/Ake­bia se­cure pri­or­i­ty re­view vouch­er

6 years ago
News Briefing

As­traZeneca sweeps two can­cer drugs to the scrap heap; Epizyme nabs pri­or­i­ty re­view for sec­ond rare can­cer NDA

6 years ago
News Briefing

Elan­co grabs $140M in deal with French phar­ma com­pa­ny; An­oth­er com­pa­ny an­nounces a coro­n­avirus vac­cine hunt

6 years ago
News Briefing
Coronavirus

The Wuhan coro­n­avirus has an of­fi­cial name: COVID-19; Rev­o­lu­tion Med­i­cines up­sizes IPO terms

6 years ago
News Briefing
Coronavirus

Omega-backed start­up sells it­self qui­et­ly; Ab­b­Vie breaks out more Rin­voq da­ta; Re­vance gets FDA date for Botox ri­val

6 years ago
News Briefing

Cure­Vac jumps in­to coro­n­avirus vac­cine race; EMA backs raft of drugs, in­clud­ing No­vo Nordisk, Es­pe­ri­on com­pounds

6 years ago
News Briefing
Coronavirus

Sanofi stops all but the most ur­gent trips to Chi­na; Flur­ry of or­phan drug des­ig­na­tions ar­rive

6 years ago
News Briefing

British Heart Foun­da­tion un­veils short­list for £30M re­search award; On­cono­va scraps Chi­na part­ner­ship

6 years ago
News Briefing

As­traZeneca scores or­phan sta­tus for PD-L1/CT­LA-4 com­bo; EMA OKs No­var­tis' MS drug Mayzent

6 years ago
News Briefing

In­ter­cep­t's NASH de­ci­sion date is de­ferred; EMA in­ves­ti­gates safe­ty of LEO Phar­ma gel

6 years ago
News Briefing

FDA grants pri­or­i­ty re­view for Rubra­ca; Arpeg­gio snags $3.2M in seed fi­nanc­ing

6 years ago
News Briefing

Xen­cor, Ve­rastem ink new deals; Scynex­is' lead drug scores again

6 years ago
News Briefing

Phath­om Phar­ma­ceu­ti­cals snatch­es up an­oth­er Cel­gene ex­ec; True North bets $74M for a stake in Bio­con Bi­o­log­ics

6 years ago
News Briefing

Here are the 52 new drugs ap­proved by the FDA in 2019. Who won? Who lost? And who just sur­vived to 2020?

6 years ago
Special
Pharma

Bio­gen hands over $45M cash to li­cense a tau project for Alzheimer's; No­var­tis launch­es a lot­tery for free dose of ...

6 years ago
News Briefing

Charles Riv­er Labs forks over $380M cash for cell ther­a­py play­er; Ax­some soars on PhI­II de­pres­sion read­out

6 years ago
News Briefing

More ques­tions than an­swers for bio­phar­ma af­ter UK elec­tion; In­ter­cept gets FDA ad­vi­so­ry date, and a PDU­FA de­lay

6 years ago
News Briefing

Eveni­ty fi­nal­ly wins EU ap­proval; US-Chi­na bi­o­log­ics CD­MO rais­es $60M

6 years ago
News Briefing

Ste­fan Fraenkel takes over as chief of In­cep­tua Group; Christi Shaw has a plan to make Yescar­ta safer

6 years ago
News Briefing

Ear­ly-stage can­cer biotech nails $85M C round; Flem­ming Orn­skov's Gal­der­ma scores 'break­through' sta­tus

6 years ago
News Briefing
First page Previous page 14151617181920 Next page Last page
A service from the Financial Times